Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 20OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 6Breast 3CNS 1

Conditions

Glioblastoma 473Brain Neoplasms 306Glioma 257Neoplasms 122Astrocytoma 88Carcinoma, Non-Small-Cell Lung 77Breast Neoplasms 70Neuroblastoma 65Central Nervous System Neoplasms 61Melanoma 58Recurrence 46Lung Neoplasms 45Pancreatic Neoplasms 41Oligodendroglioma 37Ovarian Neoplasms 36Colorectal Neoplasms 36Neoplasm Metastasis 33Sarcoma 32Medulloblastoma 28Stomach Neoplasms 27Gliosarcoma 27Lymphoma 25Prostatic Neoplasms 24Head and Neck Neoplasms 24Neurofibromatosis 1 23Rhabdomyosarcoma 21Neurofibroma, Plexiform 19Esophageal Neoplasms 19Diffuse Intrinsic Pontine Glioma 19Cholangiocarcinoma 19

Interventions

XENP 1595 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Cognitive Dysfunction × CNS × Clear all
NCT05321498 2023-09-28

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Inmune Bio, Inc.

Phase 2 Withdrawn
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡